US FDA’s Woodcock Sees Clinical Trial Reform Coming, But ‘Not Wholly Optimistic’
Executive Summary
Acting FDA commissioner says there are a lot of strong forces in the research and pharma industries that could curb efforts to make pandemic-related clinical trial reforms permanent.
You may also be interested in...
With Woodcock’s Retirement, US FDA Loses A Renaissance Woman
FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues say.
With Woodcock’s Retirement, US FDA Loses A Renaissance Woman
The FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues told the Pink Sheet.
Remote Monitoring Next Front For Regulatory Flexibility, But Will Some Accelerated Approvals Ever Be Confirmed?
Former OTAT Director Wilson Bryan says rare disease development will advance thanks to remote monitoring tools, but questions whether the long times needed to confirm clinical benefit for some drugs or biologics could come at the expense of better products.